Yi Ji

Yiji Biotech is a clinical-stage biotechnology company based in Shanghai, China, specializing in the development of innovative gene and cell therapies using CRISPR/Cas9 technology. The company's primary focus is on treating genetic blood disorders, with its lead program, YJ-001, targeting transfusion-dependent beta-thalassemia. YJ-001 is an autologous CD34+ hematopoietic stem cell therapy that utilizes CRISPR/Cas9 to edit the BCL11A enhancer, thereby inducing fetal hemoglobin production. Founded by leading scientists in the field of genome editing, Yiji Biotech aims to provide curative treatments for patients with severe inherited diseases. The company has successfully advanced its lead candidate into Phase 1/2 clinical trials following IND approval from the NMPA.